Vivier Delphine, Sharma Sai Kiran, Zeglis Brian M
Department of Chemistry, Hunter College of the City University of New York, New York, New York, USA.
Department of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Labelled Comp Radiopharm. 2018 Jul;61(9):672-692. doi: 10.1002/jlcr.3628. Epub 2018 May 14.
Over the past 25 years, antibodies have emerged as extraordinarily promising vectors for the delivery of radionuclides to tumors for nuclear imaging. While radioimmunoconjugates often produce very high activity concentrations in target tissues, they also are frequently characterized by elevated activity concentrations in healthy organs as well. The root of this background uptake lies in the complex network of biological interactions between the radioimmunoconjugate and the subject. In this review, we seek to provide an overview of these interactions and thus paint a general picture of the in vivo fate of radioimmunoconjugates. To cover the entire story, we have divided our discussion into 2 parts. First, we will address the path of the entire radioimmunoconjugate as it travels through the body. And second, we will cover the fate of the radionuclide itself, as its course can diverge from the antibody under certain circumstances. Ultimately, our goal is to provide the nuclear imaging field with a resource covering these important-yet often underestimated-pathways.
在过去25年里，抗体已成为用于将放射性核素递送至肿瘤进行核成像的极具前景的载体。虽然放射免疫缀合物通常会在靶组织中产生非常高的活性浓度，但它们在健康器官中的活性浓度也常常较高。这种本底摄取的根源在于放射免疫缀合物与受试者之间复杂的生物相互作用网络。在本综述中，我们旨在概述这些相互作用，从而描绘出放射免疫缀合物在体内命运的总体情况。为了全面阐述，我们将讨论分为两部分。首先，我们将探讨整个放射免疫缀合物在体内的运行路径。其次，我们将涵盖放射性核素本身的命运，因为在某些情况下其过程可能与抗体不同。最终，我们的目标是为核成像领域提供一份涵盖这些重要但常被低估的途径的资料。
